Chimeric Therapeutics Ltd (ASX:CHM)
A$ 0.009 0 (0%) Market Cap: 8.96 Mil Enterprise Value: 9.50 Mil PE Ratio: 0 PB Ratio: 3.00 GF Score: 0/100

Chimeric Therapeutics Ltd Investor Webinar Transcript

Oct 23, 2023 / 12:00AM GMT
Release Date Price: A$0.037 (+32.14%)
Unidentified Participant

Thank you for standing by, and welcome to today's Chimeric Therapeutics Investor Webinar discussing today's announcement of positive preliminary Phase 1 data for chlorotoxin CAR T in recurrent brain cancer. (Event Instructions) Presenting on behalf of Chimeric today, we have the CEO and Managing Director, Jennifer Chow; and Chief Medical Officer, Dr. Jason Litten. To begin, I'll hand it over to Jen. Please go ahead.

Jennifer Chow
Chimeric Therapeutics Limited - CEO and Managing Director

Thanks so much, Matt. And thank you, everybody, for taking the time this morning to join us on very short notice, to discuss the positive data that we are now seeing with CHM 1101, our chlorotoxin CAR T. I can't tell you personally how excited I am to be able to have this investor webinar today to bring everybody up to speed on this data and really to make good on the commitment that we made with this asset to bring this data to you.

So without further ado, I am going to just take you through a few introduction slides and then I'm actually going to turn

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot